THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF MAJOR DEPRESSION: A BIBLIOGRAPHICAL REVIEW
DOI:
https://doi.org/10.51891/rease.v10i8.15009Keywords:
Selective Serotonin Reuptake Inhibitors. Treatment. Depressive Disorder Major.Abstract
This article aims to review the existing literature on the use of selective serotonin reuptake inhibitors in the treatment of major depression. Major depression is a prevalent and debilitating psychiatric disorder characterized by persistent feelings of sadness, loss of interest in peaceful activities, changes in appetite and lack of sleep, and difficulty concentrating. Treatments for major depression include psychotherapeutic and pharmacological interventions, such as selective serotonin reuptake inhibitors (SSRIs), which have been highlighted as one of the first lines of treatment due to their efficacy and relatively favorable safety profile. SSRIs work by increasing the availability of serotonin in the brain, a neurotransmitter that plays a crucial role in regulating mood, anxiety and behavior. The literature review provides a detailed look at the efficacy, safety, and side effect profile of these medications, as well as practical considerations and future innovations in the field.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Atribuição CC BY